- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT01788150
Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II)
Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)
A prospective, randomized, active-control, multi-center clinical trial comparing the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) to that of the commercially available Resolute IntegrityTM Drug-Eluting Stent.
The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting Stent in patients with single, never previously treated coronary artery lesions
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Amsterdam, Alankomaat
- OLVG Amsterdam
-
Eindhoven, Alankomaat
- Catharina Hospital Eindhoven
-
Rotterdam, Alankomaat
- Maasstad Ziekenhuis
-
Rotterdam, Alankomaat
- Erasmus MC
-
Utrecht, Alankomaat
- University Medical Center Utrecht, Department of Cardiology
-
-
-
-
-
Aalst, Belgia
- OLV Ziekenhuis Aalst
-
Antwerpen, Belgia
- Middelheim Ziekenhuis
-
Genk, Belgia
- ZOL Genk
-
Liege, Belgia
- CHU Liege
-
-
-
-
-
Rouen, Ranska
- Clinique Saint-Hilaire
-
Toulouse, Ranska
- CHU de Toulouse
-
Toulouse, Ranska
- Clinique PASTEUR
-
-
-
-
-
Malmo, Ruotsi
- Skane University Hospital
-
Stockholm, Ruotsi
- Södersjukhuset
-
-
-
-
-
Hamburg, Saksa
- University Medical Center Hamburg-Eppendorf
-
Hamburg, Saksa
- Medizinisches Verzorgungszentrum Prof. Mathey, Prof. Schofer
-
-
-
-
-
Bern, Sveitsi
- Inselspital
-
-
-
-
-
Prague, Tšekki
- Vseobecna Fakultni Nemocnice Praha
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
General Inclusion Criteria
- Patient is ≥18 years old;
- Patient is eligible for percutaneous coronary intervention (PCI);
- Patient is an acceptable candidate for emergent coronary artery bypass graft (CABG) surgery;
- Patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional study;
- Female subjects of childbearing potential must have a negative pregnancy test within 7-days before the trial procedure;
- Patient or subject's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the Hospital Research Ethics Committee (HREC) of the respective investigational site; and
- Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.
Angiographic Inclusion Criteria
- Patient has either a single target lesion, or two lesions (target and non-target) located in separate coronary arteries;
If a non-target lesion is treated, it must be treated first and only with commercially available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the following conditions must be met:
- Residual diameter stenosis < 30%;
- Absence of any angiographic complications;
- Absence of ischemic symptoms; and
- Absence of significant new arrhythmia or ECG monitoring changes suggestive of ischemia.
- Reference vessel ≥ 2.5 mm and ≤ 3.5 mm in diameter by visual estimate;
- Target lesion < 20 mm in length by visual estimate (the intention is to cover the entire lesion with one stent of adequate length); and
- Target lesion stenosis ≥ 50% and < 100% by visual estimate.
Exclusion Criteria:
General Exclusion Criteria
- Patient is currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials;
- The patient requires a staged procedure of the target vessel within 6-months or a staged procedure of a non-target vessel within 30-days post-procedure;
- The target lesion requires treatment with a device other than PTCA prior to stent placement (such as, but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.);
- Any DES deployment anywhere in the target vessel within the past 9-months;
- Any BMS deployment anywhere in the target vessel within the past 6-months;
- Any previous stent placement within 10 mm (proximal or distal) of the target lesion;
Myocardial infarction within 72-hours of the index procedure, with the exception of:
- Patients who have had a STEMI and PCI to the culprit lesion may be included if they have a suitable lesion in another vessel, and have been clinically and hemodynamically stable for 72-hours;
- Patients who have had a non-STEMI may be included if their troponin levels are within the laboratory normal range within 24-hours pre-procedure.
- Co-morbid condition(s) that could limit the patient's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial;
- Concurrent medical condition with a life expectancy of less than 12-months;
- Documented left ventricular ejection fraction (LVEF) ≤ 30%;
- Unstable angina pectoris from an extra-cardiac cause (Braunwald Class A I-III);
- Known allergies to the following: Acetylsalicylic acid (ASA), Clopidogrel bisulfate, Ticlopidine, Prasugrel, Rapamycin, Zotarolimus, PEAIII AcBz, Heparin/ Bivalirudin, or contrast agent (that cannot be adequately premedicated);
- Platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 or a WBC < 3.000 cells/mm3 or hemoglobin < 100g/l;
- Acute or chronic renal dysfunction (serum creatinine > 170μmol/L);
- History of a stroke or transient ischemic attack (TIA) within the prior 6-months;
- Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6-months;
- History of bleeding diathesis or coagulopathy or will refuse blood transfusions; and
- Patients requiring ongoing anticoagulation with warfarin or dabigatran.
Angiographic Exclusion Criteria
- Total occlusion (TIMI 0 or 1);
- Target vessel has angiographic evidence of thrombus
- Target vessel is excessively tortuous or has heavy calcification;
- Significant (> 50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off;
- Target lesion is located in or supplied by an arterial or venous bypass graft;
- Ostial target lesion (within 5.0 mm of vessel origin) or any location within the left main coronary artery;
- Target lesion involves a side branch > 2.0 mm in diameter; and
- Unprotected Left Main coronary disease (stenosis > 50%).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Svelte Drug-Eluting Coronary Stent
Coronary Stenting
|
|
Active Comparator: Medtronic Resolute Integrity Drug-Eluting Stent
Coronary Stenting
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Angiographic In-Stent Late Lumen Loss (LL)
Aikaikkuna: 6-months post-procedure
|
Defined as the measurements either within the stented segment or within 5 mm proximal and distal to the stent edges.
|
6-months post-procedure
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Number of Participants Clinically-driven Target Lesion Revascularization (TLR)
Aikaikkuna: 1 year post-procedure
|
Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as unstable angina, that is, chest pain that increases in frequency, intensity or duration.
|
1 year post-procedure
|
Number of Participants Composite of Cardiac Death, MI Attributed to the Target Vessel and Clinically Driven Target Lesion Revascularization
Aikaikkuna: 1 year post-procedure
|
Composite of cardiac death, MI attributed to the target vessel and clinically driven target lesion revascularization
|
1 year post-procedure
|
Number of Participants Composite of All-cause Mortality, Any MI and Any Revascularization, Target Vessel Revascularization or Revascularization of Non Target Vessels
Aikaikkuna: 1 year post-procedure
|
Composite of all-cause mortality, any MI and any revascularization, target vessel revascularization or revascularization of non target vessels
|
1 year post-procedure
|
Number of Participants Stent Thrombosis
Aikaikkuna: 1 year post-procedure
|
The sudden occlusion of a stented coronary artery due to thrombus formation.
|
1 year post-procedure
|
Number of Participants Acute Success Rates
Aikaikkuna: From index procedure to hospital discharge, an average of 24 hours
|
Direct Stenting Success, Lesion Success, Procedure Success and Device Failure
|
From index procedure to hospital discharge, an average of 24 hours
|
Number of Participants In-stent and In-segment Angiographic Binary Restenosis Rate
Aikaikkuna: 6-months post-procedure
|
The rate which restenosis occurs
|
6-months post-procedure
|
In-stent and In-segment Minimum Lumen Diameter
Aikaikkuna: 6-months post-procedure
|
Smallest diameter in the stent or segment area
|
6-months post-procedure
|
In-segment Late Lumen Loss
Aikaikkuna: 6-months post-procedure
|
Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram
|
6-months post-procedure
|
Neointimal Hyperplasia as Measured by OCT
Aikaikkuna: 6-months post procedures
|
(% lumen volume)
|
6-months post procedures
|
Strut Coverage
Aikaikkuna: 6-months post procedure
|
(% of struts malapposed, protruding non-covered, protruding covered, non-protruding covered)
|
6-months post procedure
|
Number of Participants Target Vessel Failure
Aikaikkuna: 1 year post procedure
|
Composite endpoint of cardiac death, target vessel MI (Q or Non-Q wave), or clinically- driven target vessel revascularization (TVR) by percutaneous or surgical methods.
|
1 year post procedure
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia
- Päätutkija: Stefan Verheye, MD, PhD, Antwerp Cardiovascular Institute
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- IP-12-002
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Sepelvaltimotauti
-
Hospital Clinic of BarcelonaAstraZenecaValmisPotilaat, joille on määrä tehdä PCI (Percutaneous Coronary Intervention) CTO (krooninen kokonaistukkos)Espanja
Kliiniset tutkimukset Coronary Stenting
-
Can Tho Stroke International Services HospitalValmisAkuutti aivohalvaus | Iskeeminen aivohalvaus, akuutti | Vertebro Basilar iskemiaVietnam
-
Can Tho Stroke International Services HospitalRekrytointiAkuutti aivohalvaus | Iskeeminen aivohalvaus, akuuttiVietnam
-
Medical University of WarsawEi vielä rekrytointiaÄäreisvaltimotauti | Iskeeminen jalka | Lonkkavaltimon ahtauma | Valtimon emboliaPuola
-
Elixir Medical CorporationRekrytointi
-
Shockwave Medical, Inc.ValmisSydäninfarkti | SepelvaltimotautiYhdysvallat
-
Shockwave Medical, Inc.RekrytointiSepelvaltimotautiYhdysvallat, Espanja
-
First Affiliated Hospital of Guangxi Medical UniversityRekrytointi
-
Elixir Medical CorporationIstituto Clinico HumanitasAktiivinen, ei rekrytointiSepelvaltimotauti | Sepelvaltimon krooninen täydellinen tukos | Monisuonisepelvaltimotauti | Sepelvaltimon haarautuminen | Pitkät leesiot SepelvaltimotautiItalia
-
Medtronic VascularValmisSepelvaltimotautiYhdysvallat